China (Mainland)
Diamondsupplier 
Methotrexate CAS 59-05-2 CAS NO.59-05-2
- FOB Price: USD: 1.00-3.00 /Kilogram Get Latest Price
- Min.Order: 1 Kilogram
- Payment Terms: T/T,Other
- Available Specifications:
10KG(1-20)Kilogram10KG(20-30)Kilogram100KG(1-20)Kilogram
- Product Details
Keywords
- Methotrexate
- CAS 59-05-2
- Mexate
Quick Details
- ProName: Methotrexate CAS 59-05-2
- CasNo: 59-05-2
- Molecular Formula: C20H22N8O5
- Appearance: crystal, powder
- Application: Pharmaceutical intermediates
- DeliveryTime: 1-2 days
- PackAge: as your request
- Port: Qingdao port
- ProductionCapacity: 10 Kilogram/Day
- Purity: 99%
- Storage: stay in dry, cool and well-sealed
- Transportation: EMS,HK EMS,FEDEX,DHL,TNT
- LimitNum: 1 Kilogram
- Moisture Content: 0.01%
- Impurity: 0.001%
- Density: 1.536 g/cm3
- Melting Point: 195℃
- Water solubility: Insoluble
- Assay: 99%
Superiority
Hebei yanxi chemical co. LTD. has expanded a compositive entity from initially only as a small manufacturer. The company dedicated to the development, production and marketing of chemicals.
Methotrexate originated in the 1940s when Dr. Sidney Farber at Children's Hospital Boston was testing the effects of folic acid on acute leukemic (severe blood cancer) children.
Dr. Subbarao, who also happened to be the head of the team which had earlier synthesized folic acid (1946) readily synthesized this anti-folate and handed it over to Dr. Farber, who in turn administered it to a small group of very ill leukemic children.
The remarkable clinical improvement that was observed in these patients heralded the era of cancer chemotherapy in modern medicine. This was reported by Dr. S. Farber in the June 3rd, 1948 issue of NEJM.
In 1950 Dr. Farber founded in Boston the world's first Cancer Research Center. Methotrexate gained Food and Drug Administration (FDA) approval as an oncology drug in 1953.
Details
Methotrexate CAS 59-05-2
IUPAC Name: (2S)-2-[[4-[(2,4-Diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioicacid
Following is the structure of Methotrexate (CAS NO.59-05-2):
Empirical Formula: C20H22N8O5
Molecular Weight: 454.44 g/mol
EINECS: 200-413-8
Index of Refraction: 1.737
Molar Refractivity: 118.97 cm3
Molar Volume: 295.6 cm3
Density: 1.536 g/cm3
Melting point: 195 °C
storage temp.: −20 °C
Polarizability: 47.16 10-24cm3
Surface Tension: 96.4 dyne/cm
Water solubility: Insoluble. <0.1 g/100 mL at 19 °C
Appearance of Methotrexate (CAS NO.59-05-2): Yellow Crystaline Powder
Stability: Stable, but light sensitive and hygroscopic. Incompatible with strong acids, strong oxidizing agents. Store at -15C or below.
Product Categories: Aromatic Esters; Antibiotics for Research and Experimental Use; Antitumors for Research and Experimental Use; Biochemistry; Others (Antibiotics for Research and Experimental Use);Intermediates & Fine Chemicals; Pharmaceuticals; API's; Antitumour
Canonical SMILES: CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
Isomeric SMILES: CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
InChI: InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
InChIKey: FBOZXECLQNJBKD-ZDUSSCGKSA-N
Methotrexate History
Methotrexate originated in the 1940s when Dr. Sidney Farber at Children's Hospital Boston was testing the effects of folic acid on acute leukemic (severe blood cancer) children.
Dr. Subbarao, who also happened to be the head of the team which had earlier synthesized folic acid (1946) readily synthesized this anti-folate and handed it over to Dr. Farber, who in turn administered it to a small group of very ill leukemic children.
The remarkable clinical improvement that was observed in these patients heralded the era of cancer chemotherapy in modern medicine. This was reported by Dr. S. Farber in the June 3rd, 1948 issue of NEJM.
In 1950 Dr. Farber founded in Boston the world's first Cancer Research Center. Methotrexate gained Food and Drug Administration (FDA) approval as an oncology drug in 1953.
Methotrexate Uses
Methotrexate (CAS NO.59-05-2) was originally used as part of combination chemotherapy regimens to treat many kinds of cancers. It is commonly used (generally in combination with misoprostol) to terminate early pregnancies (i.e. as an abortifacient). It is also used to treat ectopic pregnancies. It has come into use as a treatment for some autoimmune diseases, including polymyositis, dermatomyositis, inclusion body myositis, ankylosing spondylitis, Crohn's disease, psoriasis, pustular psoriasis, psoriatic arthritis, rheumatoid arthritis, and scleroderma (see disease-modifying antirheumatic drugs). It also can be used as a antineoplastic and antirheumatic.Or can be used as a folic Acid antagonist.
Methotrexate Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| child | TDLo | intravenous | 100mg/kg/4H (100mg/kg) | BLOOD: THROMBOCYTOPENIA BLOOD: OTHER CHANGES |
Cancer Vol. 33, Pg. 1151, 1974. |
| child | TDLo | oral | 2mg/kg/12D (2mg/kg) | LUNGS, THORAX, OR RESPIRATION: COUGH LUNGS, THORAX, OR RESPIRATION: DYSPNEA |
JAMA, Journal of the American Medical Association. Vol. 209, Pg. 1861, 1969. |
| human | TDLo | intramuscular | 35mg/kg/28W (35mg/kg) | VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION LUNGS, THORAX, OR RESPIRATION: DYSPNEA LUNGS, THORAX, OR RESPIRATION: CYANOSIS |
British Medical Journal. Vol. 2, Pg. 156, 1970. |
| human | TDLo | intramuscular | 200mg/kg/5Y (200mg/kg) | LIVER: "HEPATITIS, FIBROUS (CIRRHOSIS, POST-NECROTIC SCARRING)" | Archives of Dermatology. Vol. 100, Pg. 531, 1969. |
| human | TDLo | intravenous | 4650ug/kg/4W- (4.65mg/kg) | LIVER: FATTY LIVER DEGERATION LIVER: LIVER FUNCTION TESTS IMPAIRED |
Proceedings of the American Association for Cancer Research. Vol. 5, Pg. 26, 1964. |
| human | TDLo | intravenous | 7143ug/kg (7.143mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: CHANGES IN PLATELET COUNT BLOOD: CHANGES IN LEUCOCYTE (WBC) COUNT |
Zhongguo Yaoxue Zazhi. Chinese Pharmacuetical Journal. Vol. 27, Pg. 673, 1992. |
| human | TDLo | oral | 43mg/kg/5Y (43mg/kg) | LIVER: LIVER FUNCTION TESTS IMPAIRED LIVER: OTHER CHANGES |
Archives of Dermatology. Vol. 100, Pg. 523, 1969. |
| man | TDLo | intramuscular | 214ug/kg/12D- (0.214mg/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | Clinical and Experimental Rheumatology. Vol. 14, Pg. 450, 1996. |
| man | TDLo | intravenous | 740mg/kg (740mg/kg) | GASTROINTESTINAL: OTHER CHANGES | Archives of Internal Medicine. Vol. 136, Pg. 1321, 1976. |
| man | TDLo | oral | 643ug/kg/6W-I (0.643mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Journal of Rheumatology. Vol. 14, Pg. 74, 1987. |
| man | TDLo | oral | 4286ug/kg/2.7 (4.286mg/kg) | LUNGS, THORAX, OR RESPIRATION: "FIBROSIS, FOCAL (PNEUMOCONIOSIS)" LUNGS, THORAX, OR RESPIRATION: RESPIRATORY OBSTRUCTION BLOOD: APLASTIC ANEMIA |
Clinical Rheumatology. Vol. 12, Pg. 535, 1993. |
| mouse | LD50 | intraperitoneal | 50mg/kg (50mg/kg) | Anatomical Record. Vol. 178, Pg. 465, 1974. | |
| mouse | LD50 | intravenous | 65mg/kg (65mg/kg) | Drugs in Japan Vol. 6, Pg. 841, 1982. | |
| mouse | LD50 | oral | 146mg/kg (146mg/kg) | Drugs in Japan Vol. 6, Pg. 841, 1982. | |
| mouse | LD50 | subcutaneous | 250mg/kg (250mg/kg) | National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986, | |
| mouse | LD50 | unreported | 69mg/kg (69mg/kg) | Cancer Research. Vol. 46, Pg. 2703, 1986. Link to PubMed |
|
| rat | LD50 | intraperitoneal | 6mg/kg (6mg/kg) | Drugs in Japan Vol. 6, Pg. 841, 1982. | |
| rat | LD50 | intravenous | 14mg/kg (14mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1467, 1970. Link to PubMed |
|
| rat | LD50 | oral | 135mg/kg (135mg/kg) | Drugs in Japan Vol. 6, Pg. 841, 1982. | |
| rat | LD50 | subcutaneous | 58mg/kg (58mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 93, 1992. | |
| rat | LD50 | unreported | 133ug/kg (0.133mg/kg) | United States Patent Document. Vol. #4746662, | |
| women | LDLo | intraspinal | 36mg/kg/15D (36mg/kg) | SPINAL CORD: OTHER DEGENERATIVE CHANGES GASTROINTESTINAL: NAUSEA OR VOMITING |
New England Journal of Medicine. Vol. 289, Pg. 770, 1973. |
| women | TDLo | oral | 800ug/kg/4D-I (0.8mg/kg) | BLOOD: LEUKOPENIA BLOOD: THROMBOCYTOPENIA BLOOD: OXIDANT RELATED (GPD DEFICIENT) ANEMIA |
Medical Journal of Australia. Vol. 155, Pg. 493, 1991. |
| women | TDLo | oral | 2mg/kg/17W-I (2mg/kg) | LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BLOOD: LEUKOPENIA |
Journal of Rheumatology. Vol. 14, Pg. 74, 1987. |
| women | TDLo | parenteral | 2600ug/kg (2.6mg/kg) | BRAIN AND COVERINGS: CHANGES IN CEREBRAL SPINAL FLUID LUNGS, THORAX, OR RESPIRATION: "FIBROSIS, FOCAL (PNEUMOCONIOSIS)" LUNGS, THORAX, OR RESPIRATION: DYSPNEA |
Cancer Vol. 38, Pg. 1529, 1976. |
| women | TDLo | unreported | 11400ug/kg/44 (11.4mg/kg) | LUNGS, THORAX, OR RESPIRATION: "FIBROSIS, FOCAL (PNEUMOCONIOSIS)" | Clinical and Experimental Rheumatology. Vol. 15, Pg. 583, 1997. |
| women | TDLo | unreported | 150mg/kg (150mg/kg) | SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE | Cancer Vol. 48, Pg. 2158, 1981. |
Methotrexate Consensus Reports
IARC Cancer Review: Group 3 IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 7 ,1987,p. 241.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Animal Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 26 ,1981,p. 267.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 26 ,1981,p. 267.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) . NCI Carcinogenesis Studies (ipr); No Evidence: mouse, rat CANCAR Cancer. 40 (1977),1935. . Reported in EPA TSCA Inventory.